Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

PR NewswireNov 25 08:00 ET

US Manufacturing Index Rises To 43, Highest Since 2020

Business TodayNov 16 02:13 ET

Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In...

BenzingaNov 14 08:26 ET

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

PRNewswireNov 14 08:00 ET

Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 14 07:34 ET · Ratings

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50

Yahoo FinanceNov 9 08:33 ET